Clinical Trials

120 enrolled

Myasthenia Gravis

NCT06680037 2026-04-07

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

32 enrolled

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06987539 2026-04-07

THYME

Phase 2 Recruiting

15 enrolled

Myasthenia Gravis

NCT06193889 2026-04-06

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

66 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06704269 2026-04-06

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Phase 1/2 Recruiting

15 enrolled

Myasthenia Gravis

NCT06744920 2026-04-06

RELIEVE

180 enrolled

Myasthenia Gravis

NCT06607627 2026-04-01

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Myasthenia Gravis

NCT06517758 2026-03-30

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

146 enrolled

Myasthenia Gravis

NCT07246564 2026-03-27

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

Phase 4 Recruiting

40 enrolled

Myasthenia Gravis

NCT06799247 2026-03-24

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

100 enrolled

Myasthenia Gravis

NCT06491238 2026-03-23

MG-Ex

20 enrolled

Myasthenia Gravis

NCT06463587 2026-03-19

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

264 enrolled

Myasthenia Gravis

NCT07413835 2026-03-18

Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)

6 enrolled

Myasthenia Gravis

NCT07478172 2026-03-17

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

50 enrolled

Amyotrophic Lateral Sclerosis, Charcot-Marie-Tooth Disease, Glycogen Storage Disease Type II, Muscular Atrophy, Spinal, Myasthenia Gravis, Neuromuscular Diseases, Spastic Paraplegia, Hereditary, Lambert-Eaton Myasthenic Syndrome, Postpoliomyelitis Syndrome, Motor Neuron Disease, Mitochondrial Myopathies, Myopathies, Nemaline, Myositis, Inclusion Body, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Muscular Dystrophy, Facioscapulohumeral, Myopathies, Structural, Congenital, Postural Orthostatic Tachycardia Syndrome

NCT05265273 2026-03-13

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Myasthenia Gravis

NCT07470151 2026-03-13

Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases

Autoimmune Diseases, Lupus Erythematosus, Systemic, Myasthenia Gravis, Scleroderma, Diffuse

NCT06456580 2026-03-10

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

180 enrolled

Myasthenia Gravis

NCT07039916 2026-03-06

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

231 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT04951622 2026-03-03

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

199 enrolled 11 charts

Myasthenia Gravis

NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

NCT07215949 2026-02-23

Zilucoplan for Severe gMG Exacerbations

15 enrolled

Myasthenia Gravis

NCT04833894 2026-02-18

ADAPT Jr

Myasthenia Gravis

NCT07250750 2026-02-11

Synergy-MG

Phase 1/2 Recruiting

96 enrolled

Myasthenia Gravis

NCT06220201 2026-02-10

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Phase EARLY_PHASE1 Recruiting

120 enrolled

Multiple Sclerosis, Myasthenia Gravis

NCT07284420 2026-02-09

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Phase 2 Recruiting

70 enrolled

Myasthenia Gravis

NCT07337785 2026-01-22

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

36 enrolled

Multiple Sclerosis, Myasthenia Gravis, Recurrence, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06342544 2026-01-21

IMCOMG

Phase EARLY_PHASE1 Recruiting

128 enrolled

Myasthenia Gravis

NCT06939166 2025-12-15

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Autoimmune Diseases of the Nervous System, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06392386 2025-12-05

ADAPT Jr SC

Myasthenia Gravis

NCT07215650 2025-11-17

Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)

44 enrolled

Myasthenia Gravis

NCT07072988 2025-09-24

OPTIMAGE

Phase 4 Recruiting

50 enrolled

Myasthenia Gravis

NCT06371040 2025-09-15

Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

9 enrolled

Myasthenia Gravis

NCT06659627 2025-09-09

FIT to ACT-MG

Phase EARLY_PHASE1 Recruiting

60 enrolled

Fatigue, Myasthenia Gravis

NCT07058298 2025-09-08

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

6 enrolled

Myasthenia Gravis

NCT07136844 2025-08-22

Acti-Adult

300 enrolled

Other

Charcot-Marie-Tooth Disease, Huntington Disease, Myasthenia Gravis, Myotonic Dystrophy, Neuromuscular Diseases, Obesity, Supranuclear Palsy, Progressive, Spastic Paraplegia, Hereditary, Lambert-Eaton Myasthenic Syndrome, Muscular Dystrophy, Facioscapulohumeral, Spinocerebellar Ataxias

NCT06688435 2025-08-06

A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis

50 enrolled

Myasthenia Gravis

NCT05868837 2025-08-01

REFINE

40 enrolled

Myasthenia Gravis

NCT06765161 2025-07-29

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

30 enrolled

Myasthenia Gravis

NCT06249438 2025-07-25

CAR-AID

30 enrolled

Lupus Erythematosus, Systemic, Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Scleroderma, Systemic

NCT07022197 2025-06-15

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Phase 1/2 Recruiting

27 enrolled

Myasthenia Gravis, Myositis, Neuromyelitis Optica, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT06869278 2025-06-11

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

37 enrolled

Multiple Sclerosis, Myasthenia Gravis, Recurrence

NCT06879210 2025-06-04

Application of Artificial Intelligence in Precision Medicine and Healthcare